Effect of Zilongjin Tablets on immune function of patients with lung cancer after operation / 中草药

ABSTRACT

Objective: To explore the regulatory effect of Zilongjin Tablet on immune function of postoperative patients with lung cancer from humoral immunity and cellular immunity, and to seek an effective method for comprehensive treatment of lung cancer. Methods: Sixty patients with lung cancer after operation were divided into two groups according to the digital random table, 30 in the control group and 30 in the treatment group. The control group was given routine supportive treatment after operation. The treatment group was given Zilongjin Tablets (4 tablets, 3 times/d) with routine supportive treatment on day 3 after operation. The indexes of immunoglobulin (IgA, IgG, IgM), T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+), and NK cells were compared between the two groups. Results: On day 2 after operation, IgA, IgG, IgM, CD3+, CD4+, CD4+/CD8+ in the two groups decreased compared with those before operation, and the difference was statistically significant (P 0.05). On day 14 after operation, the levels of IgA, IgG, IgM, CD3+, CD4+, CD4+/CD8+, NK in the two groups increased, the NK of the control group and the IgA, IgG, IgM, CD3+, CD4+, CD4+/CD8+ of the treatment group were significant differences compared with the 2nd day after operation (P < 0.05). Moreover, there were significant differences in IgA, IgG, CD4+, CD4+/CD8+, NK between the two groups on day 14 after operation (P < 0.05). Conclusion: Patients with lung cancer have immunosuppressive status in the early postoperative period. Zilongjin Tablets can improve the postoperative humoral immunity and cellular immunity of patients with lung cancer, promote the recovery of immune function and enhance their anti-tumor ability.